Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Thursday

Syros Pharmaceuticals (NASDAQ:SYRS) will be releasing its earnings data before the market opens on Thursday, October 31st. Analysts expect Syros Pharmaceuticals to post earnings of ($0.67) per share for the quarter.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, July 31st. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.09. On average, analysts expect Syros Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syros Pharmaceuticals Trading Down 8.0 %

SYRS stock opened at $2.07 on Friday. The company has a market capitalization of $55.33 million, a PE ratio of -0.41 and a beta of 1.59. Syros Pharmaceuticals has a one year low of $1.43 and a one year high of $8.17. The company’s 50 day moving average price is $1.84 and its two-hundred day moving average price is $4.10. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.46 and a current ratio of 3.46.

Insider Activity at Syros Pharmaceuticals

In other news, CFO Jason Haas purchased 45,344 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average cost of $1.68 per share, for a total transaction of $76,177.92. Following the acquisition, the chief financial officer now directly owns 124,552 shares of the company’s stock, valued at $209,247.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Conley Chee acquired 50,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was acquired at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the acquisition, the chief executive officer now owns 72,504 shares of the company’s stock, valued at $109,481.04. This trade represents a 200.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jason Haas acquired 45,344 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was bought at an average price of $1.68 per share, with a total value of $76,177.92. Following the completion of the acquisition, the chief financial officer now directly owns 124,552 shares in the company, valued at approximately $209,247.36. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 130,707 shares of company stock worth $206,491 in the last three months. 12.26% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SYRS has been the topic of several research reports. Piper Sandler reissued an “overweight” rating and set a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. StockNews.com raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. JMP Securities decreased their price target on shares of Syros Pharmaceuticals from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, HC Wainwright lowered their price target on shares of Syros Pharmaceuticals from $15.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.